title: Segmentally enclosed thrombolysis in percutaneous transluminal angioplasty for femoropopliteal occlusions: a report from a pilot study.
abstract: Segmentally enclosed thrombolysis (SET) was performed immediately following 34 percutaneous transluminal angioplasties (PTAs) for femoropopliteal occlusions. The dilated segment was sealed off with a double balloon catheter, and recombinant tissue plasminogen activator (rt-PA) 1 mg/ml and heparin 200 IU/ml were injected between the balloons. The catheter was removed after 30 min and heparin treatment was continued for 24 h. Alpha-2-antiplasmin was initially reduced by 13% and normalized 2 h after SET, indicating that only small amounts of free plasmin were liberated during thrombolysis. No clinically relevant changes in plasma fibrinogen occurred. Two puncture site hemorrhages did not coincide with the coagulopathy induced by SET. One-year patency was 80%. Early rethrombosis occurred in 9% versus 41% in our previous series on standard PTA for femoropopliteal occlusions (p less than 0.001). Therefore, SET is considered beneficial in reducing the incidence of early rethrombosis.
authors.affiliation: Department of Clinical Physiology/Nuclear Medicine, Bispebjerg Hospital, University of Copenhagen, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Jørgensen
authors.forename: K H
authors.initials: KH
authors.lastname: Tønnesen
authors.forename: J D
authors.initials: JD
authors.lastname: Nielsen
authors.forename: P
authors.initials: P
authors.lastname: Holstein
authors.forename: J
authors.initials: J
authors.lastname: Bülow
authors.forename: M
authors.initials: M
authors.lastname: Jørgensen
authors.forename: E
authors.initials: E
authors.lastname: Andersen
mesh_terms: D000368:Aged; D000800:Angioplasty, Balloon; D005260:Female; D005263:Femoral Artery; D006493:Heparin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011150:Popliteal Artery; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000628:therapy*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014654:Vascular Patency
chemical_list: D006493:Heparin; D010959:Tissue Plasminogen Activator